Eszopiclone is NOT an Anxiolytic and Should NOT Be Used as Primary Treatment for Anxiety Disorders
Eszopiclone is FDA-approved exclusively for insomnia, not anxiety disorders, and clinical guidelines do not recommend it as an anxiolytic agent. While some research suggests potential anxiolytic effects when treating comorbid insomnia with anxiety, this does not establish eszopiclone as appropriate monotherapy for anxiety.
FDA-Approved Indication
Eszopiclone is approved only for treating sleep-onset and sleep-maintenance insomnia 1. The drug label makes no mention of anxiety as an approved indication. It is classified as a benzodiazepine receptor agonist (BzRA) hypnotic, not an anxiolytic medication.
Clinical Guideline Recommendations
For Insomnia Treatment
The American Academy of Sleep Medicine (2017) recommends eszopiclone specifically for sleep onset and sleep maintenance insomnia at 2-3 mg doses 2. The 2008 AASM guidelines position eszopiclone as a first-line pharmacologic option for primary insomnia, but explicitly note that sedating antidepressants should be used "especially when used in conjunction with treating comorbid depression/anxiety" 3. This clearly distinguishes between hypnotics (like eszopiclone) and medications appropriate for anxiety.
For Anxiety Disorders
The Japanese Society of Anxiety and Related Disorders/Japanese Society of Neuropsychopharmacology (2023) guideline for social anxiety disorder does not include eszopiclone among recommended treatments 4. SSRIs (fluvoxamine, paroxetine, escitalopram) and CBT are the evidence-based treatments for anxiety disorders.
Important Clinical Distinction: Comorbid Conditions vs. Primary Treatment
The evidence shows eszopiclone may improve anxiety symptoms only in the context of treating comorbid insomnia:
In patients with GAD and insomnia, eszopiclone combined with escitalopram improved both sleep and anxiety measures compared to escitalopram alone 5. However, this was combination therapy where escitalopram (an SSRI) was the primary anxiolytic.
In perimenopausal women with insomnia, hot flashes, and anxiety symptoms, eszopiclone improved all symptoms 6, but again, this was in the context of treating primary insomnia with comorbid symptoms.
In MDD patients with insomnia, switching from benzodiazepines to eszopiclone improved insomnia and showed trends toward improved anxiety scores 7, but the primary diagnosis was depression with insomnia, not an anxiety disorder.
Critical Safety Concerns
Withdrawal-Emergent Anxiety
The FDA label specifically warns that eszopiclone can CAUSE anxiety as an adverse effect. In a 6-month study, anxiety was reported in 3.7% of eszopiclone patients versus 2.1% on placebo 1. During withdrawal after 44 nights of use, 1% of patients spontaneously reported new-onset anxiety, along with abnormal dreams, hyperesthesia, and neurosis—none of which occurred in the placebo group 1.
Cognitive and Behavioral Impairment
Eszopiclone 3 mg causes next-morning psychomotor and memory impairment lasting up to 11.5 hours post-dose, even when patients don't subjectively perceive impairment 1. This poses significant risks for driving and daily functioning.
Other Serious Adverse Effects
The FDA warns of complex sleep-related behaviors (sleepwalking, sleep-driving, sleep-eating), cognitive changes, and the American College of Physicians (2016) notes observational data linking hypnotics to increased risk of dementia, fractures, and major injury 8, 9.
Appropriate Clinical Algorithm
For patients presenting with anxiety:
- Use evidence-based anxiolytics: SSRIs (first-line), SNRIs, or buspirone
- Consider CBT or other psychotherapy
- If benzodiazepines are needed for acute severe anxiety, use short-term only
For patients with anxiety AND insomnia:
- Treat the anxiety disorder with appropriate anxiolytic medication (SSRI/SNRI)
- Implement CBT-I as first-line for insomnia 9
- If pharmacotherapy for insomnia is needed after CBT-I fails, eszopiclone can be added to ongoing anxiolytic treatment 3, 9
- Use shared decision-making regarding short-term hypnotic use, discussing risks of cognitive impairment, falls, and potential for withdrawal-emergent anxiety 9
For primary insomnia without anxiety disorder:
- CBT-I first-line 9
- If pharmacotherapy needed: eszopiclone 2-3 mg is appropriate 2
- Monitor for emergence of anxiety as an adverse effect
Common Pitfall to Avoid
Do not prescribe eszopiclone as monotherapy for anxiety disorders simply because some studies show anxiety improvement in patients with comorbid insomnia. The anxiety improvements in those studies occurred either with concurrent SSRI therapy 5 or as secondary benefits of improved sleep in patients whose primary complaint was insomnia 6. Eszopiclone lacks the mechanism of action, FDA approval, and guideline support for use as an anxiolytic agent.